Danaher Corporation (DHR)
|Net Income (ttm)||5.45B|
|Ex-Dividend Date||Sep 29, 2021|
|Day's Range||300.33 - 302.66|
|52-Week Range||210.71 - 333.73|
|Price Target||332.29 (+10.3%)|
|Est. Earnings Date||Oct 21, 2021|
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to t... [Read more...]
In 2020, Danaher's revenue was $22.28 billion, an increase of 24.42% compared to the previous year's $17.91 billion. Earnings were $3.65 billion, an increase of 21.21%.Financial Statements
According to 21 analysts, the average rating for Danaher stock is "Buy." The 12-month stock price forecast is 332.29, which is an increase of 10.26% from the latest price.
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WASHINGTON, Oct. 12, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company"), the global science and technology innovator, today released its 2021 Sustainability Report and highlighted the ...
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher Corp (DHR) has been struggling lately, but the selling pressure may be coming to an end soon.
Danaher (DHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Danaher (DHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...
Danaher (NYSE:DHR) has outperformed the market over the past 90 days by 10.15%, generating a 10.28% return for its investors over the time period. Now, given this information, it may seem like price app...
Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4%...
ATLANTA, Sept. 28, 2021 /PRNewswire/ -- Beckman Coulter today announced the launch of its DxU Iris Workcell at the AACC Annual Scientific Meeting & Clinical Lab Expo.
We have narrowed down our search to five U.S. corporate behemoths that have strong growth potential for the rest of 2021. These are: AAPL, MSFT, NVDA, DHR and COST.
WASHINGTON, Sept. 21, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 ...
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
WASHINGTON, Sept. 14, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.21 per share of its common sto...
We have narrowed down our search to five large-cap low-beta stocks that have provided double-digit returns in the past three months. These are: DHR, COST, CARR, MSI, and RSG.
Huntington's Jill Garvey on the stocks presenting opportunity amid fears of rising rates
Jill Garvey, Senior Vice President & Senior Wealth Strategist at Huntington Private Bank, joins Worldwide Exchange to discuss her market outlook.
Danaher (DHR) closed at $332.43 in the latest trading session, marking a +0.3% move from the prior day.
FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX builds on cadence of innovation in biopharma with Biologics Explorer, enabling protein characterization analysis for the ZenoTOF 7600 system
FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX presents the latest capillary electrophoresis solution, the BioPhase 8800 system, the only multi-capillary system for CE-SDS.
WASHINGTON , Aug. 30, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of Aldevron. As previously announced, Aldevron will operate as a ...
Danaher (DHR), with a 25% rise in shares in the past three months, benefits from strong demand, solid product offerings and synergies from buyouts. Shareholder-friendly policies add to its appeal.